Ascendis Pharma A/S (NASDAQ:ASND) Given “Overweight” Rating at Cantor Fitzgerald

Posted by Brenda Bartman on Sep 28th, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $300.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 30.56% from the stock’s previous close.

ASND has been the topic of several other reports. Wall Street Zen cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday. Wedbush reiterated an “outperform” rating and set a $327.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. Morgan Stanley dropped their target price on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a report on Tuesday, September 1st. Weiss Ratings upgraded shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, Raymond James Financial lowered shares of Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 price target for the company. in a report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S presently has an average rating of “Buy” and a consensus target price of $310.75.

View Our Latest Stock Analysis on Ascendis Pharma A/S

Ascendis Pharma A/S Stock Up 1.9%

Ascendis Pharma A/S stock traded up $4.18 during midday trading on Friday, hitting $229.78. The stock had a trading volume of 221,424 shares, compared to its average volume of 695,233. The business has a fifty day moving average price of $251.52 and a 200 day moving average price of $242.29. Ascendis Pharma A/S has a 12 month low of $186.05 and a 12 month high of $282.15. The stock has a market cap of $14.33 billion, a P/E ratio of 17.81 and a beta of 0.35. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. Research analysts predict that Ascendis Pharma A/S will post 3.69 EPS for the current year.

Insider Buying and Selling at Ascendis Pharma A/S

In other news, Director Jean-Jacques Bienaimé acquired 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the transaction, the director directly owned 2,900 shares in the company, valued at $714,357. This trade represents a 222.22% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at $810,570. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

Large investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC acquired a new position in shares of Ascendis Pharma A/S during the second quarter worth approximately $380,000. IFP Advisors Inc grew its holdings in Ascendis Pharma A/S by 3,491.7% in the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after buying an additional 419 shares in the last quarter. Squarepoint Ops LLC increased its position in Ascendis Pharma A/S by 1,714.3% in the 2nd quarter. Squarepoint Ops LLC now owns 9,686 shares of the biotechnology company’s stock valued at $2,583,000 after acquiring an additional 10,286 shares during the period. Baird Financial Group Inc. acquired a new stake in Ascendis Pharma A/S in the 2nd quarter valued at approximately $2,863,000. Finally, Allworth Financial LP raised its stake in Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 122 shares in the last quarter.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.